SCYNEXIS, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $42.0M
- Price
- $4.22
- % Change (Daily % change from the live per-ticker quote feed.)
- -11.72%
- Volume
- 343.9K
About
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Quick stats
Shares outstanding9.9M
Computed float9.8M
Float / shares98.1%
Cash runway (months)7.6
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001178253
Websitehttps://www.scynexis.com
AI Summary
AI-generated1/17
minorbullishclinical trial
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS completed a Phase 1 study of SCY-770, a first-in-class oral direct AMPK activator for ADPKD, showing the drug was well tolerated with a favorable safety profile at higher doses than previously evaluated.
The study enrolled 25 healthy participants across three cohorts with doses up to 750 mg once daily or 500 mg twice daily; safety was consistent with prior clinical experience across roughly 300 cumulative participants.
The Phase 2 proof-of-concept study in ADPKD patients remains on track to initiate in Q4 2026, with SCY-770 holding FDA Orphan Drug Designation for the indication.
Red flags
- risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study design on the anticipated timeline or at all